KalVista Pharmaceuticals Files 8-K
Ticker: KALV · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
KalVista dropped an 8-K, check it for financial updates.
AI Summary
KalVista Pharmaceuticals, Inc. filed an 8-K on December 5, 2024, to report on its results of operations and financial condition, and to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond its classification as a current report.
Why It Matters
This 8-K filing indicates KalVista Pharmaceuticals is providing an update on its financial condition and operations, which could contain material information for investors.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting operational and financial information, not a specific event like a merger or major announcement.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- Carbylan Therapeutics, Inc. (company) — Former Company Name
- Carbylan Biosurgery, Inc (company) — Former Company Name
- 0000950170-24-133693 (filing_id) — Accession Number
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the provided text does not detail specific dollar amounts or financial metrics.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is December 05, 2024.
What is KalVista Pharmaceuticals, Inc.'s primary business classification?
KalVista Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What were KalVista Pharmaceuticals' former company names?
KalVista Pharmaceuticals was formerly known as Carbylan Therapeutics, Inc. and Carbylan Biosurgery, Inc.
Where is KalVista Pharmaceuticals, Inc. headquartered?
KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-12-05 16:17:12
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
Filing Documents
- kalv-20241205.htm (8-K) — 42KB
- kalv-ex99_1.htm (EX-99.1) — 176KB
- 0000950170-24-133693.txt ( ) — 340KB
- kalv-20241205.xsd (EX-101.SCH) — 24KB
- kalv-20241205_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On December 5, 2024, KalVista Pharmaceuticals, Inc. (the "Company") reported its financial results for the fiscal quarter ended October 31, 2024. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report. The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release dated December 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: December 5, 2024 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer (Principal Financial and Accounting Officer)